# ConcertAI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/concertai

- Industry: Software
- Headquarters: Cambridge, US
- Website: www.concertai.com
- Total disclosed funding: $300M
- Latest round: Series C (Mar 29, 2022)
- Investors on record: 5

## About

Founded in 2018 and based in Massachusetts, US, ConcertAI LLC operates as an AI-powered SaaS data company that develops medical research tools for oncology research and data analytics. The CEO of the company is Eron Kelly. In March 2022, ConcertAI LLC raised USD 150 million in series C funding led by new investor Sixth Street Growth which values ConcertAI LLC at USD 1.9 billion post-money. ConcertAI LLC develops STAR, an enterprise solution for patient insights, and SPRINT, a cloud-based solution for contracting. The company's products include RWD360™, which is a repository of pan tumor clinical data; Patient360™ to identify base rates of clinical characteristics, disease severity measures, and treatment outcomes; and Genome360™ to identify patients by a variant in a given gene, such as mutation, amplification, rearrangement, etc. The company also evaluates the clinical trial efficiency research using custom patient surveys to help pharmaceutical companies evaluate currently approved treatments and also develop new treatments for cancer of bladder, breast, liver, lung, etc.

## Funding rounds

- Series C, Mar 29, 2022, $150M — Sixth Street
- Series B, Jan 13, 2020, $150M — AllianceBernstein, Maverick Capital, SymphonyAI Group, Declaration Partners

## Investors

- AllianceBernstein (https://capitalatlas.ai/funds/alliancebernstein) — Series B
- Maverick Capital (https://capitalatlas.ai/funds/maverick-capital) — Series B
- SymphonyAI Group (https://capitalatlas.ai/funds/symphonyai-group) — Series B
- Declaration Partners (https://capitalatlas.ai/funds/declaration-partners) — Series B
- Sixth Street (https://capitalatlas.ai/funds/sixth-street) — Series C